Copyright
©The Author(s) 2021.
World J Gastroenterol. Dec 7, 2021; 27(45): 7813-7830
Published online Dec 7, 2021. doi: 10.3748/wjg.v27.i45.7813
Published online Dec 7, 2021. doi: 10.3748/wjg.v27.i45.7813
Table 4 Comparison of the present study with other studies on multimodality management of gallbladder cancer
| Parameter | Our study | Patkar et al[4], 2018 | Creasy et al[15], 2019 |
| Sample size | 274 | 400 | 437 |
| Patients who underwent complete resection | 172 | 320 | 255 |
| Unresectable | 102 | 80 | 182 |
| Major liver resection, (%) | Yes (7) | No | Yes (24.3) |
| Incidental GBC, (%) | 35 | 40 | 60.7 |
| R1 resection, n (%) | 11/172 (6.4) | 10/320 (3.1) | 15/255 (5.9) |
| Neoadjuvant in resectable group, n (%) | 43/172 (25) | 83/320 (25.9) | 16/255 (6.3) |
| Final stage III/IV, n (%) | 106/172 (61.6) | 232/400 (58) | 306/437 (70) |
| LN positivity, n (%) | 56/172 (32) | 98/320 (30.62) | NA |
| Residual disease in incidental cases, n (%) | 29/73 (39.7) | 68/160 (42.5) | 172/276 (62.3) |
| Adjuvant therapy, n (%) | 117/147 (79.6) | 206/320 (64.4) | 78/255 (30.7) |
| Recurrence, n (%) | 71/172 (41.2) | 98/320 (30.6) | NA |
| Dying of disease, n (%) | 69/172 (40.1) | 45/320 (14) | 149/255 (58.4) |
| Estimated 3 yr OS, (%) | 56 | 64 | NA |
| Estimated 5 yr OS, (%) | 43.5 | NA | 43 (only survivors) |
| Estimated 3 yr DFS, (%) | 49.2 | 49 | 36 |
- Citation: Goel S, Aggarwal A, Iqbal A, Talwar V, Mitra S, Singh S. Multimodality management of gallbladder cancer can lead to a better outcome: Experience from a tertiary care oncology centre in North India. World J Gastroenterol 2021; 27(45): 7813-7830
- URL: https://www.wjgnet.com/1007-9327/full/v27/i45/7813.htm
- DOI: https://dx.doi.org/10.3748/wjg.v27.i45.7813